Frequently Asked Questions

Adjunctive lumateperone 42 mg significantly improved depressive symptoms and overall illness severity versus placebo in adults with major depressive disorder who had an inadequate response to 1 or 2 antidepressant therapies. On the primary outcome, change in MADRS Total score from baseline to day 43 favored lumateperone + ADT with a least squares mean difference of 4.9 points versus placebo (95% CI, 6.38 to 3.44; effect size = 0.61; P < .0001). On the key secondary outcome, CGI-S score also improved with lumateperone + ADT (LSMD = 0.7; 95% CI, 0.85 to 0.48; effect size = 0.67; P < .0001).

The discussion states that clinically meaningful, significant improvements were seen by day 8 with lumateperone + antidepressant therapy and persisted throughout the 6-week study. The formal primary analysis was at day 43, where lumateperone remained significantly better than placebo on both MADRS and CGI-S.

Yes. Lumateperone + ADT significantly improved patient-reported depression and anxiety severity from baseline to day 43 versus placebo + ADT, based on QIDS-SR-16 and GAD-7 scores, respectively. The article reports significance for both measures, although the specific numerical between-group values are presented in the study table rather than the main text.

Yes. In the subgroup with MDD and DSM-5 anxious distress, lumateperone + ADT significantly improved both MADRS Total score and CGI-S score from baseline to day 43. Nearly half of patients met anxious distress criteria at baseline: 99 patients (40.7%) in the placebo + ADT group and 110 patients (45.6%) in the lumateperone + ADT group.

The study enrolled adults aged 1865 years with DSM-5 major depressive disorder who had an inadequate response to 1 or 2 antidepressant therapies during the current major depressive episode. Inadequate response was defined as less than 50% improvement after at least 6 weeks of antidepressant treatment at an adequate dose. At screening and baseline, patients also had to have MADRS Total score 24, CGI-S score 4, and QIDS-SR-16 score 14.

This was a phase 3, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose trial. A total of 485 patients were randomized 1:1 to adjunctive placebo + antidepressant therapy or adjunctive lumateperone 42 mg + antidepressant therapy across 54 sites in 6 countries. The study included a 2-week screening period, a 6-week double-blind treatment period, and a 1-week safety follow-up.

Treatment-emergent adverse events occurred more often with lumateperone + ADT than with placebo + ADT: 58.1% versus 46.5%. Most adverse events in both groups were mild or moderate, accounting for more than 98% of TEAEs. The most common TEAEs that were at least 5% and more than twice placebo were dry mouth, fatigue, and tremor.

EPS-related treatment-emergent adverse events were uncommon but more frequent with lumateperone + ADT than placebo + ADT: 6.2% versus 2.9%. Tremor was the main EPS-related event, occurring in 12 patients receiving lumateperone and 1 patient receiving placebo; none of the tremor cases with lumateperone were severe, most began in the first 2 weeks, and mean duration was 14.6 days (SD 10.65). The article also reports no notable changes on AIMS, BARS, or SAS total scores, and low incidence of akathisia and Parkinsonism based on scale shifts.

The study found no notable end-of-treatment changes in weight, body mass index, or waist circumference with lumateperone + ADT. Changes in cardiometabolic parameters and prolactin were not clinically significant and were generally similar between groups. Potentially clinically significant weight change of at least 7% up or down from baseline was rare, occurring in less than 1% of patients.

No suicidal behavior occurred during treatment in either group, and emergence of suicidal ideation was lower with lumateperone + ADT than placebo + ADT: 3 patients (1.4%) versus 8 patients (3.5%). There were no TEAEs of suicidal ideation in the lumateperone group and no TEAEs of mania or hypomania in either group. For QT safety, no lumateperone-treated patients had a QT Fridericia-corrected interval of at least 480 ms or an increase greater than 60 ms from baseline.

The main limitations are that the trial excluded patients with treatment-resistant illness, imminent suicidal risk, or comorbid psychiatric illnesses other than MDD, which may limit generalizability. The study was also short term, with only 6 weeks of double-blind treatment, so it does not by itself establish long-term efficacy or safety.